Swiss perspectives in 10 languages

Novartis leukaemia drug approved in Switzerland

Scientist looking at blood
Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells Keystone

Basel-based pharmaceutical company Novartis has received approval for its personalised cell therapy Kymriah in Switzerland. Children and adults who suffer from certain types of blood cancer will be able to undergo the one-time treatment, which is set to cost CHF370,000 ($371,000). 

Kymriah is already registered in the US, the EU and other countries. In the US, the treatment costs $475,000; the EU has said it will work with health officials to find fair, value-based pricing. 

As in the US, pricing in Switzerland is set to be linked to the success of the therapy, although the details were still being worked out, said Kay Moeller-Heske, head of oncology at Novartis Switzerland, on Monday. The drug is not covered by obligatory health insurance, he added.

Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells. Novartis is the first Swiss pharmaceutical company to be approved for such therapy. 

The number of possible treatment centres in Switzerland would initially be very limited as the Kymriah cell therapy places high demands on the production facilities and the staff, according to Moeller-Heske. 

He pointed out, however, that the number of patients was expected to be very low at first: a “low two-digit number” of patients, with four or five being children. 

What is Kymriah and what does it do? 

Kymriah, formerly known as CTL019, is a type of immunotherapyExternal link known as a chimeric antigen receptor T cell (CAR-T) therapy, and is first of its kind to receive FDA approval. Kymriah is intended for use in patients with a specific type of childhood leukaemia known as ALLExternal link. It is a one-time treatment that involves modifying a patient’s own T-cells – a type of white blood cell – and then using them to target and destroy cancer cells. Until now, ALL has had a very poor survival rate – fewer than 10% of patients survive five yearsExternal link

More

Popular Stories

Most Discussed

News

Gestational diabetes increases the risk of adult-onset diabetes

More

Gestational diabetes found to increase risk of adult-onset diabetes

This content was published on A research team from the Lake Geneva region has identified persistent dysfunctions in glucose regulation in women with gestational diabetes. In the long term, this can increase the risk of adult-onset diabetes by up to ten times.

Read more: Gestational diabetes found to increase risk of adult-onset diabetes
The Graubünden village of Brienz has to be evacuated by midday on Sunday

More

Swiss village must be evacuated by midday on Sunday

This content was published on The village of Brienz-Brinzauls in eastern Switzerland, which is threatened by a rockfall, must be evacuated by 1pm on Sunday. All residents must leave the village.

Read more: Swiss village must be evacuated by midday on Sunday
Former judge in Chur found guilty of rape

More

Former Swiss judge found guilty of rape

This content was published on A former judge of the Graubünden Administrative Court in eastern Switzerland has been found guilty of rape, sexual harassment and threatening a former trainee.

Read more: Former Swiss judge found guilty of rape

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR